Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Mayo Clinic identifies key cellular process in prostate and other cancers

15.02.2005


Mayo Clinic researchers are the first to identify an interaction between two cellular proteins -- Skp2 and FOXO1 -- that is important for the growth and survival of cancer cells. Researchers also show that this interaction can be chemically reversed to stop cancer tumor growth -- a strategy that may lead to new and better cancer treatments.



Their report appears as an electronic advance article of PNAS, the Proceedings of the National Academy of Sciences ( http://www.pnas.org/cgi/reprint/102/5/1649). The research was performed on human cells in the laboratory and was found effective against human cancer cells. Researchers say it will be at least a year before the discovery can be applied in a human clinical trial.

The Findings


For the first time, the Mayo Clinic research group provides laboratory evidence to describe a new mechanism by which cells lose the protection of tumor suppressors -- and therefore become vulnerable to cancerous cell growth. In particular, they show that Skp2 is the cellular player that interacts with FOXO1 by tagging it for destruction. This degradation of FOXO1 by high levels of Skp2, in turn, abolishes the ability of FOXO1 to suppress tumors. The result of their experiment indicates that human prostate cancer grows without the protection of the tumor suppressor protein FOXO1. Importantly, they also show that this loss of function can be reversed -- even in the presence of high levels of Skp2, by using chemicals that inhibit protein destruction, and thus block Skp2’s action against FOXO1.

Significance of the Finding

"The major finding of our studies is that the tumor suppression function of FOXO1 is abolished due to Skp2-mediated protein degradation," says Haojie Huang, Ph.D., the urology researcher who performed the study. Co-investigator Donald J. Tindall, Ph.D., adds, "We’ve discovered a viable therapeutic target in human cancers, especially those with high levels of Skp2."

The Mayo Clinic researchers’ findings suggest a promising new treatment target at which drug designers can aim new therapies for prostate cancer, as well as a number of other human cancers in which elevated levels of Skp2 have already been documented. These include cancers of the breast, lymphatic leukemia, small cell lung cancer and certain cancers of the mouth and colorectal cancer.

About Prostate Cancer

Prostate cancer is the second most common cause of cancer in men (skin cancer is first) and the second leading cause of cancer death in American men, exceeded only by lung cancer. In 2005, the American Cancer Society estimates 232,000 new cases will be diagnosed. While one in six men will be diagnosed with prostate cancer in his lifetime, only one in 33 will die of it. Because of the widespread disability and death that prostate cancer causes, finding new strategies to develop better treatments is an important public health goal.

Background Biology

The Mayo Clinic researchers wanted to understand the relationship between a group of proteins known as tumor suppressors that belong to the FOXO1 family, and the Skp2 protein. When tumor suppressors fail, the result is abnormal cell growth that can eventually transform healthy cells into cancerous cells. In particular, the Mayo Clinic team wanted to find out what disables FOXO1 tumor suppressor, and how it works -- in hopes of reversing the process to find a new cancer therapy strategy.

The Experiment

The Mayo Clinic research team knew from previous research:

  • FOXO1 possesses tumor suppressor functions. Its tumor suppression works two ways: by curbing cell reproduction and by inducing cells to kill themselves -- especially cancer cells.
  • Some tumor suppressors lose their effectiveness through a means known as the "ubiquitin pathway." This pathway is a cellular strategy for attaching an identifying marker to the tumor suppressor that targets it for destruction.
  • Skp2 is known to target several tumor suppressors for destruction.
  • FOXO1 is suited to being targeted for destruction via the ubiquitin pathway.

The researchers noted that high levels of Skp2 were associated with low levels of FOXO1 in many human cancer cells, including prostate cancer -- and then combined the lines of evidence outlined above to design experiments to answer the specific question: Do elevated levels of Skp2 drive down and disable FOXO1, thus resulting in loss of its tumor suppression ability? The answer is yes.

Robert Nellis | EurekAlert!
Further information:
http://www.mayo.edu
http://www.mayoclinic.com

More articles from Life Sciences:

nachricht Climate Impact Research in Hannover: Small Plants against Large Waves
17.08.2018 | Leibniz Universität Hannover

nachricht First transcription atlas of all wheat genes expands prospects for research and cultivation
17.08.2018 | Leibniz-Institut für Pflanzengenetik und Kulturpflanzenforschung

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Smallest transistor worldwide switches current with a single atom in solid electrolyte

17.08.2018 | Physics and Astronomy

Robots as Tools and Partners in Rehabilitation

17.08.2018 | Information Technology

Climate Impact Research in Hannover: Small Plants against Large Waves

17.08.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>